. 2019 Dec; 58(Suppl 7):vii59-vii67.
doi: 10.1093/rheumatology/kez308.

Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors

Sophia C Weinmann 1 David S Pisetsky 1 
  • PMID: 31816080
  •     70 References
  •     43 citations


Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the regulatory interactions that limit T cell cytotoxicity to tumours. Current agents target either CTLA-4 or the PD-1/PD-L1 axis. Because checkpoints may also regulate autoreactivity, immune checkpoint inhibitor therapy is complicated by side effects known as immune-related adverse events (irAEs). The aim of this article is to review the mechanisms of these events. irAEs can involve different tissues and include arthritis and other rheumatic manifestations. The frequency of irAEs is related to the checkpoint inhibited, with the combination of agents more toxic. Because of their severity, irAEs can limit therapy and require immunosuppressive treatment. The mechanisms leading to irAEs are likely similar to those promoting anti-tumour responses and involve expansion of the T cell repertoire; furthermore, immune checkpoint inhibitors can affect B cell responses and induce autoantibody production. Better understanding of the mechanisms of irAEs will be important to improve patient outcome as well as quality of life during treatment.

Keywords: B cell; CTLA-4; PD-1; PD-L1; T cell; arthritis; autoantibodies; autoreactivity; checkpoint; co-stimulation.

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H Nishimura, T Okazaki, +8 authors, T Honjo.
Science, 2001 Feb 24; 291(5502). PMID: 11209085
Highly Cited.
Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sabina Sandigursky, Adam Mor.
Curr Rheumatol Rep, 2018 Sep 08; 20(10). PMID: 30191417    Free PMC article.
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Xuexiang Du, Fei Tang, +14 authors, Yang Liu.
Cell Res, 2018 Feb 24; 28(4). PMID: 29472691    Free PMC article.
Highly Cited.
Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
J Rogado, J M Sánchez-Torres, +13 authors, R Colomer.
Eur J Cancer, 2019 Jan 27; 109. PMID: 30682533
Highly Cited.
PD-1 and PD-1 ligands: from discovery to clinical application.
Taku Okazaki, Tasuku Honjo.
Int Immunol, 2007 Jul 04; 19(7). PMID: 17606980
Highly Cited. Review.
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
Kenneth D Lute, Kenneth F May, +8 authors, Yang Liu.
Blood, 2005 Jul 23; 106(9). PMID: 16037385    Free PMC article.
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E A Tivol, F Borriello, +3 authors, A H Sharpe.
Immunity, 1995 Nov 01; 3(5). PMID: 7584144
Highly Cited.
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
Laura C Cappelli, Anna Kristina Gutierrez, +10 authors, Clifton O Bingham.
Ann Rheum Dis, 2016 Jun 17; 76(1). PMID: 27307501    Free PMC article.
Highly Cited.
Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4.
Barbara L Goldstein, Lydia Gedmintas, Derrick J Todd.
Arthritis Rheumatol, 2014 Feb 28; 66(3). PMID: 24574239
Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.
Steven Orlov, Farnaz Salari, Lawrence Kashat, Paul G Walfish.
J Clin Endocrinol Metab, 2015 Mar 10; 100(5). PMID: 25751110
The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis.
Amalia P Raptopoulou, George Bertsias, +7 authors, Dimitrios T Boumpas.
Arthritis Rheum, 2010 May 28; 62(7). PMID: 20506224
Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
Maria E Suarez-Almazor, Sang T Kim, Noha Abdel-Wahab, Adi Diab.
Arthritis Rheumatol, 2017 Jan 14; 69(4). PMID: 28085999
Highly Cited. Review.
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
Marie Kostine, Léa Rouxel, +18 authors, FHU ACRONIM.
Ann Rheum Dis, 2017 Nov 18; 77(3). PMID: 29146737
Highly Cited.
Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity.
C Calabrese, E Kirchner, +2 authors, L H Calabrese.
RMD Open, 2017 Apr 14; 3(1). PMID: 28405474    Free PMC article.
Highly Cited.
CTLA4 blockade broadens the peripheral T-cell receptor repertoire.
Lidia Robert, Jennifer Tsoi, +11 authors, Antoni Ribas.
Clin Cancer Res, 2014 Mar 04; 20(9). PMID: 24583799    Free PMC article.
Highly Cited.
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
Michiel van der Vlist, Jurgen Kuball, Timothy R D Radstake, Linde Meyaard.
Nat Rev Rheumatol, 2016 Aug 20; 12(10). PMID: 27539666
Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response.
Melanie H Smith, Anne R Bass.
Arthritis Care Res (Hoboken), 2017 Nov 11; 71(3). PMID: 29125905
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Frederick Arce Vargas, Andrew J S Furness, +32 authors, Sergio A Quezada.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576375    Free PMC article.
Highly Cited.
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
David Y Oh, Jason Cham, +5 authors, Lawrence Fong.
Cancer Res, 2016 Dec 30; 77(6). PMID: 28031229    Free PMC article.
Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
Shirwa Sheik Ali, Allison L Goddard, +4 authors, Ruth Ann Vleugels.
JAMA Dermatol, 2014 Oct 17; 151(2). PMID: 25321335
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood.
Katrin Klocke, Shimon Sakaguchi, Rikard Holmdahl, Kajsa Wing.
Proc Natl Acad Sci U S A, 2016 Apr 14; 113(17). PMID: 27071130    Free PMC article.
Highly Cited.
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H Nishimura, M Nose, +2 authors, T Honjo.
Immunity, 1999 Sep 15; 11(2). PMID: 10485649
Highly Cited.
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.
Laura C Cappelli, Julie R Brahmer, +6 authors, Ami A Shah.
Semin Arthritis Rheum, 2018 Mar 27; 48(3). PMID: 29573850    Free PMC article.
Highly Cited.
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
Douglas B Johnson, Ryan J Sullivan, +18 authors, Joseph I Clark.
JAMA Oncol, 2015 Dec 04; 2(2). PMID: 26633184
Highly Cited.
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.
Sang Taek Kim, Jean Tayar, +6 authors, Adi Diab.
Ann Rheum Dis, 2017 Aug 24; 76(12). PMID: 28830882
Highly Cited.
Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways.
Cuiping Liu, Juean Jiang, +7 authors, Xueguang Zhang.
Arthritis Res Ther, 2015 Nov 27; 17. PMID: 26608464    Free PMC article.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Jeffrey Weber, Mario Mandala, +32 authors, CheckMate 238 Collaborators.
N Engl J Med, 2017 Sep 12; 377(19). PMID: 28891423
Highly Cited.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Giao Q Phan, James C Yang, +14 authors, Steven A Rosenberg.
Proc Natl Acad Sci U S A, 2003 Jun 27; 100(14). PMID: 12826605    Free PMC article.
Highly Cited.
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
A M Menzies, D B Johnson, +17 authors, G V Long.
Ann Oncol, 2016 Oct 01; 28(2). PMID: 27687304
Highly Cited.
CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients.
Jennifer Pieper, Jessica Herrath, +3 authors, Vivianne Malmström.
BMC Immunol, 2013 Aug 07; 14. PMID: 23915385    Free PMC article.
Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation.
Denise Lau, Linda Yu-Ling Lan, +10 authors, Patrick C Wilson.
Sci Immunol, 2017 Aug 08; 2(7). PMID: 28783670    Free PMC article.
Highly Cited.
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
P Waterhouse, J M Penninger, +6 authors, T W Mak.
Science, 1995 Nov 10; 270(5238). PMID: 7481803
Highly Cited.
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Spencer C Wei, Colm R Duffy, James P Allison.
Cancer Discov, 2018 Aug 18; 8(9). PMID: 30115704
Highly Cited. Review.
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.
Miguel F Sanmamed, Lieping Chen.
Cell, 2018 Oct 06; 175(2). PMID: 30290139    Free PMC article.
Highly Cited. Review.
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.
Krista Dubin, Margaret K Callahan, +9 authors, Jedd D Wolchok.
Nat Commun, 2016 Feb 03; 7. PMID: 26837003    Free PMC article.
Highly Cited.
Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression.
Yanxia Guo, Alice M Walsh, +18 authors, Sunil Nagpal.
PLoS One, 2018 Mar 01; 13(2). PMID: 29489833    Free PMC article.
Highly Cited.
Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome.
Masaya Kobayashi, Seiji Kawano, +9 authors, Shunichi Kumagai.
J Rheumatol, 2005 Nov 03; 32(11). PMID: 16265694
Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.
Merav Lidar, Eitan Giat, +6 authors, Gal Markel.
Autoimmun Rev, 2018 Jan 18; 17(3). PMID: 29341936
Highly Cited.
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
Noha Abdel-Wahab, Mohsin Shah, Maria A Lopez-Olivo, Maria E Suarez-Almazor.
Ann Intern Med, 2018 Jan 04; 168(2). PMID: 29297009
Highly Cited. Systematic Review.
Immune Checkpoint Inhibitor Toxicity.
David J Palmieri, Matteo S Carlino.
Curr Oncol Rep, 2018 Aug 02; 20(9). PMID: 30066230
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.
Emma C de Moel, Elisa A Rozeman, +7 authors, Diane van der Woude.
Cancer Immunol Res, 2018 Nov 15; 7(1). PMID: 30425107
Immune inhibitory receptors.
J V Ravetch, L L Lanier.
Science, 2000 Oct 06; 290(5489). PMID: 11021804
Highly Cited. Review.
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
J C Osorio, A Ni, +11 authors, M D Hellmann.
Ann Oncol, 2016 Dec 22; 28(3). PMID: 27998967    Free PMC article.
Highly Cited.
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
Hye Sun Kuehn, Weiming Ouyang, +33 authors, Gulbu Uzel.
Science, 2014 Sep 13; 345(6204). PMID: 25213377    Free PMC article.
Highly Cited.
Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma.
Bethsabée Garel, Nora Kramkimel, +2 authors, Nicolas Dupin.
Joint Bone Spine, 2016 May 03; 84(2). PMID: 27133763
Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma.
Joshua S Manusow, Leila Khoja, +2 authors, Efrem D Mandelcorn.
J Immunother Cancer, 2014 Dec 18; 2(1). PMID: 25516805    Free PMC article.
Is autoimmunity the Achilles' heel of cancer immunotherapy?
Carl H June, Jeremy T Warshauer, Jeffrey A Bluestone.
Nat Med, 2017 May 06; 23(5). PMID: 28475571
Highly Cited.
Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy.
Jing Hughes, Nalini Vudattu, +4 authors, Kevan C Herold.
Diabetes Care, 2015 Mar 26; 38(4). PMID: 25805871    Free PMC article.
Highly Cited.
Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management.
Stefania Stucci, Raffaele Palmirotta, +6 authors, Franco Silvestris.
Oncol Lett, 2017 Nov 09; 14(5). PMID: 29113194    Free PMC article.
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
Ayelet Sivan, Leticia Corrales, +9 authors, Thomas F Gajewski.
Science, 2015 Nov 07; 350(6264). PMID: 26541606    Free PMC article.
Highly Cited.
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.
Richard V Parry, Jens M Chemnitz, +6 authors, James L Riley.
Mol Cell Biol, 2005 Oct 18; 25(21). PMID: 16227604    Free PMC article.
Highly Cited.
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
Jérôme Galon, Helen K Angell, Davide Bedognetti, Francesco M Marincola.
Immunity, 2013 Jul 31; 39(1). PMID: 23890060
Highly Cited. Review.
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy.
Myriam N Bouchlaka, Gail D Sckisel, +16 authors, William J Murphy.
J Exp Med, 2013 Oct 02; 210(11). PMID: 24081947    Free PMC article.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
T-cell regulation by CD28 and CTLA-4.
M L Alegre, K A Frauwirth, C B Thompson.
Nat Rev Immunol, 2002 Mar 22; 1(3). PMID: 11905831
Highly Cited. Review.
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.
Angeliki M Stamatouli, Zoe Quandt, +11 authors, Kevan C Herold.
Diabetes, 2018 Jun 26; 67(8). PMID: 29937434    Free PMC article.
Highly Cited. Review.
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Marie Vétizou, Jonathan M Pitt, +35 authors, Laurence Zitvogel.
Science, 2015 Nov 07; 350(6264). PMID: 26541610    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.
Laura C Cappelli, Anna Kristina Gutierrez, Clifton O Bingham, Ami A Shah.
Arthritis Care Res (Hoboken), 2016 Dec 21; 69(11). PMID: 27998041    Free PMC article.
Highly Cited. Systematic Review.
Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.
Laura C Cappelli, Ami A Shah, Clifton O Bingham.
Rheum Dis Clin North Am, 2016 Nov 29; 43(1). PMID: 27890174    Free PMC article.
Early B cell changes predict autoimmunity following combination immune checkpoint blockade.
Rituparna Das, Noffar Bar, +10 authors, Kavita M Dhodapkar.
J Clin Invest, 2018 Jan 09; 128(2). PMID: 29309048    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab.
David R Minor, Stephen R Bunker, Judith Doyle.
J Clin Oncol, 2013 Jun 05; 31(20). PMID: 23733772
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, +20 authors, KEYNOTE-006 investigators.
N Engl J Med, 2015 Apr 22; 372(26). PMID: 25891173
Highly Cited.
Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok.
Science, 2018 Mar 24; 359(6382). PMID: 29567705    Free PMC article.
Highly Cited. Review.
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.
Jarushka Naidoo, Laura C Cappelli, +13 authors, Julie R Brahmer.
Oncologist, 2017 Jun 04; 22(6). PMID: 28576858    Free PMC article.
The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma.
B Lee, A Wong, +4 authors, S Sandhu.
Ann Oncol, 2016 Feb 11; 27(6). PMID: 26861600
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.
T Takahashi, T Tagami, +5 authors, S Sakaguchi.
J Exp Med, 2000 Jul 19; 192(2). PMID: 10899917    Free PMC article.
Highly Cited.
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
Vassiliki A Boussiotis.
N Engl J Med, 2016 Nov 03; 375(18). PMID: 27806234    Free PMC article.
Highly Cited. Review.
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.
Samantha L Bucktrout, Jeffrey A Bluestone, Fred Ramsdell.
Genome Med, 2018 Nov 01; 10(1). PMID: 30376867    Free PMC article.
Management of immune checkpoint inhibitor-related adverse events: A review of case reports.
Xiaoyan Si, Peng Song, +12 authors, Li Zhang.
Thorac Cancer, 2020 Jan 24; 11(3). PMID: 31970923    Free PMC article.
Neurologic complications of immune checkpoint inhibitors.
Alexandra M Haugh, John C Probasco, Douglas B Johnson.
Expert Opin Drug Saf, 2020 Mar 04; 19(4). PMID: 32126176    Free PMC article.
A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer.
Ammar Al-Obaidi, Nathaniel A Parker, +2 authors, Jeremy M Deutsch.
Cureus, 2020 Jun 17; 12(5). PMID: 32542148    Free PMC article.
Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors.
Alberto Vogrig, Sergio Muñiz-Castrillo, +2 authors, Jérôme Honnorat.
Ther Adv Neurol Disord, 2020 Jul 09; 13. PMID: 32636932    Free PMC article.
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.
Josée Golay, Alain E Andrea.
Antibodies (Basel), 2020 May 24; 9(2). PMID: 32443877    Free PMC article.
Progress of immune checkpoint LAG-3 in immunotherapy.
Chanchan Shan, Xing Li, Jian Zhang.
Oncol Lett, 2020 Sep 24; 20(5). PMID: 32963613    Free PMC article.
Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions.
David Bauché, Smita Mauze, +11 authors, Drake Laface.
J Immunother Cancer, 2020 Nov 01; 8(2). PMID: 33127658    Free PMC article.
Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies.
Kaijian Zhou, Shu Guo, +2 authors, Guoxin Liang.
Front Cell Dev Biol, 2020 Nov 13; 8. PMID: 33178688    Free PMC article.
Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers.
Natasha A Jain, Songzhu Zhao, +4 authors, Dwight H Owen.
Cancer Manag Res, 2020 Nov 26; 12. PMID: 33235503    Free PMC article.
Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature.
Marcos C B Oliveira, Marcelo H de Brito, Mateus M Simabukuro.
Front Neurol, 2020 Dec 29; 11. PMID: 33362680    Free PMC article.
Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer.
Matthew D Kerr, David A McBride, Arun K Chumber, Nisarg J Shah.
Expert Opin Drug Discov, 2020 Sep 02; 16(1). PMID: 32867561    Free PMC article.
Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis.
Shuo Zhang, Ziyue Zhou, +3 authors, Xiaofeng Zeng.
Ther Adv Chronic Dis, 2021 Feb 27; 12. PMID: 33633822    Free PMC article.
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Agnese Paderi, Roberta Giorgione, +7 authors, Lorenzo Antonuzzo.
Cancers (Basel), 2021 Mar 07; 13(4). PMID: 33670634    Free PMC article.
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown.
Ying Zhang, Xuemei Xie, +8 authors, Judy Lieberman.
Proc Natl Acad Sci U S A, 2021 Feb 26; 118(9). PMID: 33627408    Free PMC article.
Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.
Luisa Maria Griewing, Claudia Schweizer, +14 authors, Markus Hecht.
BMC Cancer, 2021 Mar 26; 21(1). PMID: 33761922    Free PMC article.
Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
Sophia H Verspohl, Tobias Holderried, +2 authors, Valentin S Schäfer.
Ther Adv Musculoskelet Dis, 2021 Apr 30; 13. PMID: 33912248    Free PMC article.
Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis.
Jianyang Fu, Wang-Zhong Li, +4 authors, Changqing Xie.
Front Oncol, 2021 May 11; 11. PMID: 33968750    Free PMC article.
Systematic Review.
Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy.
Joanna Roopkumar, Shadi Swaidani, +14 authors, Alok A Khorana.
Med (N Y), 2021 May 27; 2(4). PMID: 34036293    Free PMC article.
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
Alan H Baik, Olalekan O Oluwole, +4 authors, Javid J Moslehi.
Circ Res, 2021 May 04; 128(11). PMID: 33934609    Free PMC article.
Immunotherapy-related gastritis: Two case reports and literature review.
Rachel Woodford, Karen Briscoe, Richard Tustin, Ankit Jain.
Clin Med Insights Oncol, 2021 Jul 23; 15. PMID: 34290539    Free PMC article.
Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
Sujatha Kumar, Srimoyee Ghosh, +10 authors, David Jenkins.
MAbs, 2021 Jul 28; 13(1). PMID: 34313545    Free PMC article.
Immune Checkpoint Inhibitors in Advanced NSCLC: [18F]FDG PET/CT as a Troubleshooter in Treatment Response.
Cristina Ferrari, Giulia Santo, +5 authors, Giuseppe Rubini.
Diagnostics (Basel), 2021 Sep 29; 11(9). PMID: 34574022    Free PMC article.
A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.
Neeraj Chhabra, Joseph Kennedy.
J Med Toxicol, 2021 Apr 08; 17(4). PMID: 33826117    Free PMC article.
Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy.
Hsin-Yu Liu, Christophe Pedros, +3 authors, Amnon Altman.
J Immunother Cancer, 2021 Oct 01; 9(9). PMID: 34588224    Free PMC article.
Embracing cancer immunotherapy with vital micronutrients.
Raymond C-F Yuen, Shiu-Ying Tsao.
World J Clin Oncol, 2021 Oct 12; 12(9). PMID: 34631438    Free PMC article.
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer.
Leyre Zubiri, Gabriel E Molina, +27 authors, Kerry L Reynolds.
J Immunother Cancer, 2021 Sep 22; 9(9). PMID: 34544895    Free PMC article.
Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation.
Lilia Bardoscia, Nadia Pasinetti, +2 authors, Angela Sardaro.
Front Pharmacol, 2021 Nov 19; 12. PMID: 34790123    Free PMC article.
Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma.
Pramod Savarapu, Basel Abdelazeem, +2 authors, Arvind Kunadi.
J Community Hosp Intern Med Perspect, 2021 Nov 23; 11(6). PMID: 34804411    Free PMC article.
Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury.
Zengfu Zhang, Jialin Zhou, +4 authors, Dawei Chen.
Front Immunol, 2021 Dec 21; 12. PMID: 34925345    Free PMC article.
Non-invasive Detection of Immunotherapy-Induced Adverse Events.
Carolina A Ferreira, Pedram Heidari, +5 authors, Umar Mahmood.
Clin Cancer Res, 2021 Jul 14; 27(19). PMID: 34253581    Free PMC article.
Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review.
Omar Abdihamid, Abeid Omar, Tibera Rugambwa.
Ecancermedicalscience, 2022 Jan 21; 15. PMID: 35047065    Free PMC article.
Rheumatological Adverse Events Following Immunotherapy for Cancer.
Ioana Cretu, Bogdan Cretu, +4 authors, Ruxandra Ionescu.
Medicina (Kaunas), 2022 Jan 22; 58(1). PMID: 35056402    Free PMC article.
Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study.
Alice Gravier-Dumonceau, Roxana Ameli, +44 authors, Romain Marignier.
Neurology, 2021 Nov 21; 98(6). PMID: 34799461    Free PMC article.
Anti-Programmed Death Ligand-1 Induced Acute Vision Loss in a Patient With Cancer-Associated Retinopathy.
Muhammad Z Chauhan, Hana A Mansour, Maroof K Zafar, Sami H Uwaydat.
Cureus, 2022 Feb 12; 14(1). PMID: 35145825    Free PMC article.
Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases.
Yoshiaki Yura, Masakazu Hamada.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35159059    Free PMC article.
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.
Nanruoyi Zhou, Maria A Velez, +14 authors, Aaron Lisberg.
Lung Cancer, 2021 Sep 11; 161. PMID: 34507111    Free PMC article.
Cardiotoxicity risk factors with immune checkpoint inhibitors.
Zachary L Brumberger, Mary E Branch, +3 authors, Sujethra Vasu.
Cardiooncology, 2022 Mar 13; 8(1). PMID: 35277208    Free PMC article.
Checkpoint Inhibitors and Induction of Celiac Disease-like Condition.
Aaron Lerner, Carina Benzvi.
Biomedicines, 2022 Mar 26; 10(3). PMID: 35327411    Free PMC article.
Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis.
Alejandro Olivares-Hernández, Edel Del Barco Morillo, +8 authors, María Dolores Ludeña de la Cruz.
Biomedicines, 2022 Feb 26; 10(2). PMID: 35203569    Free PMC article.
Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment.
Zhaoting Li, Yingyue Ding, +7 authors, Quanyin Hu.
Nat Commun, 2022 Apr 08; 13(1). PMID: 35387972    Free PMC article.
Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors.
Lijun Zhao, Yang Li, +11 authors, Xia He.
J Immunother, 2022 Mar 08; 45(4). PMID: 35250004    Free PMC article.
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.
Daniel Ronen, Aseel Bsoul, +4 authors, Rabea Asleh.
Vaccines (Basel), 2022 Apr 24; 10(4). PMID: 35455289    Free PMC article.
Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report.
Yi Feng, Chengyang Li, +4 authors, Tianshu Liu.
Front Oncol, 2022 Apr 19; 12. PMID: 35433482    Free PMC article.